Clinical Trial Update: Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating TTFields at 150 kHz with gemcitabine or gemcitabine plus nab-paclitaxel for frontline advanced pancreatic adenocarcinoma; status not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• TTFields (Tumor Treating Fields)

Snippet

Sponsor: NovoCure Ltd. | Conditions: Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN